Translational Modeling Strategies for Orally Administered Drug Products: Academic, Industrial and Regulatory Perspectives
- 13 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Pharmaceutical Research
- Vol. 37 (6), 1-13
- https://doi.org/10.1007/s11095-020-02814-y
Abstract
During non-clinical and clinical development of a new molecular entity (NME), modeling and simulation (M&S) are routinely used to predict the exposure and pharmacokinetics (PK) of the drug compound in humans. The basic methodology and output are generally understood across all functional disciplines. However, this understanding is mostly restricted to traditional methods such as those in simplified kinetic models and void of adequate mechanistic foundation to address questions beyond the observed clinical data. In the past two decades, alternative and more mechanistic methods, particularly for describing absorption, distribution, excretion and metabolism (ADME) of drugs have been developed and applied under the general umbrella of physiologically-based pharmacokinetic (PBPK) methods. Their mechanistic nature gives the ability to ask many other questions which were not traditionally asked and provide some logically and evidenced-based potential answers. Whilst traditional PK methods are mainstream and understood by most scientists, mechanistic absorption models alongside other PBPK approaches are still deemed eclectic, despite making significant strides in the fundamental science as well as regulatory acceptance. On November 3rd, a short course was held at the annual American Association of Pharmaceutical Scientists (AAPS) meeting in San Antonio, Texas. The different talks were tailored to provide a basis or rationale for the subject, introduction to fundamental principles with historical perspective, a critique of the state-of-the-art, examples of successful application of the methods across different phases of the drug development process and the specific standards these mechanistic models should meet to be fully reliable from a regulatory perspective.Keywords
Funding Information
- Fonds Wetenschappelijk Onderzoek (12R2119N))
This publication has 41 references indexed in Scilit:
- Combining the ‘bottom up’ and ‘top down’ approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical dataBritish Journal of Clinical Pharmacology, 2014
- PBTK modelling platforms and parameter estimation tools to enable animal-free risk assessmentRegulatory Toxicology and Pharmacology, 2014
- PBPK models for the prediction of in vivo performance of oral dosage formsEuropean Journal of Pharmaceutical Sciences, 2013
- Evaluation of gastrointestinal drug supersaturation and precipitation: Strategies and issuesInternational Journal of Pharmaceutics, 2012
- Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patientsCancer Chemotherapy and Pharmacology, 2012
- Anatomical, Physiological and Metabolic Changes with Gestational Age during Normal PregnancyClinical Pharmacokinetics, 2012
- pH-Induced Precipitation Behavior of Weakly Basic Compounds: Determination of Extent and Duration of Supersaturation Using Potentiometric Titration and Correlation to Solid State PropertiesPharmaceutical Research, 2012
- The migrating motor complex: control mechanisms and its role in health and diseaseNature Reviews Gastroenterology & Hepatology, 2012
- Pharmaceutical applications of cyclodextrins: basic science and product developmentJournal of Pharmacy and Pharmacology, 2010
- Effect of PCBs on the lactational transfer of methyl mercury in mice: PBPK modelingEnvironmental Toxicology and Pharmacology, 2009